Zaira R. Palacios-Baena

Dr. Zaira R. Palacios-Baena

Unit of infectious diseases, University Hospital Virgen Macarena, Seville, Spain, Seville, Spain
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
ZPZaira R. Palacios-Baena
Zaira R. Palacios-Baena
MGMaddalena Giannella
Maddalena Giannella
DMDavide Manissero
Davide Manissero
JRJesus Rodríguez-Baño
Jesus Rodríguez-Baño
PVPierluigi Viale
Pierluigi Viale
CLChristopher Longshaw
Christopher Longshaw
Rapid and widespread increases in carbapenem resistance (CR) necessitate identification of risk factors to guide appropriate interventions. We aimed to identify risk factors for CR Gram-negative infection through a systematic literature review. We searched MEDLINE (via OvidSP and PubMed) and Embase (via OvidSP) databases and the Cochrane Central Register of Controlled Trials. Prospective or retrospective cohort and case-control studies reporting quantitative data on risk factors associated with infections due to CR Gram-negative pathogens in hospitalised patients were eligible. Studies included hospitalised patients with CR infection caused by Gram-negative bacterial pathogens (Enterobacterales and non-fermenters). Searches were conducted in January 2018/December 2019 to identify studies published since 2007. Risk factor data were extracted and grouped by factor. The primary metric was proportion of studies reporting a significant association with CR infection for each factor. In total, 92 studies were identified. Risk factors most frequently reported as significantly associated with CR infection (>10 studies) were previous antibiotic use (91.1% [72/79 studies]); previous carbapenem use (82.6% [57/69]); previous colonisation (72.7% [8/11]); mechanical ventilation (66.7% [36/54]); previous intensive care unit stay (64.4% [38/59]); dialysis (61.1% [11/18]); catheter (58.0% [40/69]); length of stay in hospital (54.5% [30/55]); comorbidities (52.7% [39/74]); APACHE II (51.7% [15/29]); and intubation (51.4% [18/35]). Risk factors were mostly consistent across different species and sites of infection. Several variables, particularly previous antibiotic use, are strong risk factors for CR infection. Interventions to mitigate against CR infection should target these factors.

1 February 2016 in Journal of Infection
Verified
Journal Article
Closed access
ZPZaira R. Palacios-Baena
Zaira R. Palacios-Baena
JOJesús Oteo-Iglesias
Jesús Oteo-Iglesias
CCCarmen Conejo
Carmen Conejo
NLNieves Larrosa
Nieves Larrosa
GBGermán Bou
Germán Bou
GCGEIH-GEMARA (SEIMC) and REIPI Group for CPE
GEIH-GEMARA (SEIMC) and REIPI Group for CPE

31 March 2015 in BMJ Open
Verified
Journal Article
Open access
CRClara Rosso-Fernández
Clara Rosso-Fernández
JSJesús Sojo-Dorado
Jesús Sojo-Dorado
ABAngel Barriga
Angel Barriga
LLLucía Lavín-Alconero
Lucía Lavín-Alconero
ZPZaira R. Palacios-Baena
Zaira R. Palacios-Baena
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
Introduction: Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ago, it was not investigated in accordance with current standards and so is not used in clinical practice except in desperate situations. It is one of the so-called neglected antibiotics of high potential interest for the future. Methods and analysis: The main objective of this project is to demonstrate the clinical non-inferiority of intravenous fosfomycin with regard to meropenem for treating bacteraemic urinary tract infections (UTI) caused by ESBL-EC. This is a ‘real practice’ multicentre, open-label, phase III randomised controlled trial, designed to compare the clinical and microbiological efficacy, and safety of intravenous fosfomycin (4 g/6 h) and meropenem (1 g/8 h) as targeted therapy for this infection; a change to oral therapy is permitted after 5 days in both arms, in accordance with predetermined options. The study design follows the latest recommendations for designing trials investigating new options for multidrug-resistant bacteria. Secondary objectives include the study of fosfomycin concentrations in plasma and the impact of both drugs on intestinal colonisation by multidrug-resistant Gram-negative bacilli. Ethics and dissemination: Ethical approval was obtained from the Andalusian Coordinating Institutional Review Board (IRB) for Biomedical Research (Referral Ethics Committee), which obtained approval from the local ethics committees at all participating sites in Spain (22 sites). Data will be presented at international conferences and published in peer-reviewed journals. Discussion: This project is proposed as an initial step in the investigation of an orphan antimicrobial of low cost with high potential as a therapeutic alternative in common infections such as UTI in selected patients. These results may have a major impact on the use of antibiotics and the development of new projects with this drug, whether as monotherapy or combination therapy. Trial registration number: NCT02142751. EudraCT no: 2013-002922-21. Protocol V.1.1 dated 14 March 2014.

19 August 2017 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZPZaira R. Palacios-Baena
Zaira R. Palacios-Baena
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
ECEsther Calbo
Esther Calbo
BABenito Almirante
Benito Almirante
PVPierluigi Viale
Pierluigi Viale
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
There is little information about the efficacy of active alternative drugs to carbapenems except β-lactam/β-lactamase inhibitors for the treatment of bloodstream infections (BSIs) due to extended-spectrum β-lactamase–producing Enterobacteriaceae (ESBL-E). The objective of this study was to assess the outcomes of patients with BSI due to ESBL-E who received empiric therapy with such drugs (other active drugs [OADs]) or carbapenems. A multinational retrospective cohort study of patients with BSI due to ESBL-E who received empiric treatment with OADs or carbapenems was performed. Cox regression including a propensity score for receiving OADs was performed to analyze 30-day all-cause mortality as main outcome. Clinical failure and length of stay were also analyzed. Overall, 335 patients were included; 249 received empiric carbapenems and 86 OADs. The most frequent OADs were aminoglycosides (43 patients) and fluoroquinolones (20 patients). Empiric therapy with OADs was not associated with mortality (hazard ratio [HR], 0.75; 95% confidence interval [CI], .38–1.48) in the Cox regression analysis. Propensity score–matched pairs, subgroups, and sensitivity analyses did not show different trends; specifically, the adjusted HR for aminoglycosides was 1.05 (95% CI, .51–2.16). OADs were neither associated with 14-day clinical failure (adjusted odds ratio, 0.62; 95% CI, .29–1.36) nor length of hospital stay. We were unable to show that empiric treatment with OAD was associated with a worse outcome compared with carbapenems. This information allows more options to be considered for empiric therapy, at least for some patients, depending on local susceptibility patterns of ESBL-E.

20 December 2016 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
ZPZaira R. Palacios-Baena
Zaira R. Palacios-Baena
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
MCMarina De Cueto
Marina De Cueto
PVPierluigi Viale
Pierluigi Viale
MVMario Venditti
Mario Venditti
OGon behalf of the REIPI/ESGBIS/INCREMENT Group
on behalf of the REIPI/ESGBIS/INCREMENT Group
Background. Bloodstream infections (BSIs) due to ESBL-producing Enterobacteriaceae (ESBL-E) are frequent yet outcome prediction rules for clinical use have not been developed. The objective was to define and validate a predictive risk score for 30 day mortality. Methods. A multinational retrospective cohort study including consecutive episodes of BSI due to ESBL-E was performed; cases were randomly assigned to a derivation cohort (DC) or a validation cohort (VC). The main outcome variable was all-cause 30 day mortality. A predictive score was developed using logistic regression coefficients for the DC, then tested in the VC. Results. The DC and VC included 622 and 328 episodes, respectively. The final multivariate logistic regression model for mortality in the DC included age >50 years (OR = 2.63; 95% CI: 1.18–5.85; 3 points), infection due to Klebsiella spp. (OR = 2.08; 95% CI: 1.21–3.58; 2 points), source other than urinary tract (OR = 3.6; 95% CI: 2.02–6.44; 3 points), fatal underlying disease (OR = 3.91; 95% CI: 2.24–6.80; 4 points), Pitt score >3 (OR = 3.04; 95 CI: 1.69–5.47; 3 points), severe sepsis or septic shock at presentation (OR = 4.8; 95% CI: 2.72–8.46; 4 points) and inappropriate early targeted therapy (OR = 2.47; 95% CI: 1.58–4.63; 2 points). The score showed an area under the receiver operating curve (AUROC) of 0.85 in the DC and 0.82 in the VC. Mortality rates for patients with scores of < 11 and ≥11 were 5.6% and 45.9%, respectively, in the DC, and 5.4% and 34.8% in the VC. Conclusions. We developed and validated an easy-to-collect predictive scoring model for all-cause 30 day mortality useful for identifying patients at high and low risk of mortality.

1 August 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
ARA. Rojas
A. Rojas
ZPZaira R. Palacios-Baena
Zaira R. Palacios-Baena
LLLuis Eduardo López-Cortés
Luis Eduardo López-Cortés
JBJesus Rodríguez Baño
Jesus Rodríguez Baño